Did you know today is #NationalAIDay?
At #BullFrogAI, we're proud to harness the power of artificial intelligence to help biopharma organizations uncover deeper insights from complex data, improve decision making, and advance drug development.
$BFRG's CEO, Vin Singh, spoke to @pulse2news about our focus on reducing drug development inefficiencies through AI, upcoming milestones, and how the company's growth will center on expanding into CNS disorders and broader pharma applications.
Read more: https://t.co/Cye9noplUi
Excited to share $BFRG CEO Vin Singh has been highlighted as part of @AuthorityMgzine's “Meet the Entrepreneurs Pushing the Boundaries of AI” series.
Read the full Q&A here: https://t.co/tieC0VaBhx
$BFRG CEO shares his perspective on traditional weighted spreadsheets and scorecard-based approaches often fall short, how AI-driven decision frameworks can help organizations make more transparent, auditable, and defensible decisions.
@TheAIJournal1 ➡️ https://t.co/zMwzp4vvlF
Did you know that $BFRG offers a free data prep assessment? Eliminate errors, harmonize formats, and unlock insights faster, whether you’re running clinical trials, managing omics data, or aggregating real-world evidence.Get yours here ➡️ https://t.co/u2ix9yymUQ
$BFRG announces new commercial leadership team to
execute growth strategy for its integrated pharma AI platform:
John Stewart, SVP, Commercial Sales
Eric Roos, SVP, Business Development & Corporate Strategy
Tom Hazel, Ph.D., VP, Scientific Operations
🔗 https://t.co/A9VCtIrLCQ
Better decisions start with better data.
When data is fragmented or inconsistent, generating reliable and explainable insights becomes far more difficult.
That’s why trustworthy, usable, and auditable data foundations matter before the AI analysis even begins.
At $BFRG, we use causal #AI and graph-based analytics to model how genes, pathways, and clinical signals actually interact, helping teams move beyond correlations to biological drivers that matter.
Learn how we turn biological complexity into clarity ➡️ https://t.co/WctxfU59GF
CEO of $BFRG, Vin Singh, discussed with BioPharma Boardroom how causal AI, multimodal data analysis and precision patient targeting could help reduce clinical trial failure rates and accelerate smarter drug development. ⬇️ https://t.co/LqY08RT8b2
Meet Kristin Bigos $BFRG's CNS Senior Director.
She is a highly accomplished researcher and assistant professor of medicine, psychiatry, and pharmacology at Johns Hopkins University’s School of Medicine.
Learn more about our team: https://t.co/Th7WCxFPHM
$BFRG Provides Business Update: Strengthened Balance Sheet Supports Continued Execution as Company Aims to Ramp Commercial Activity with Global Pharmaceutical and Biotechnology Partners. Read the full letter here: https://t.co/kpMMUt3KHN
#ICYMI $BFRG’s latest webinar is live. With “Turning AI Recommendations into Clear, Defensible Decisions” you can learn how a decision-support tool can strengthen defensibility, transparency and consistency in biopharma decision-making. ⬇️ https://t.co/8SW4nM8uWI
#ICYMI Discover Pharma recently featured $BFRG's latest announcement of signing a commercial agreement with top 5 global pharma company to identify novel target in major depressive disorder.
Learn more ⬇️ https://t.co/ISAyI3y95t
$BFRG announces a commercial agreement with a top 5 global pharmaceutical company in 2025 by revenue, to apply the Company’s proprietary bfLEAP® platform to identify and prioritize novel drug targets in major depressive disorder. 🔗 https://t.co/WJquGFZ6tW
You don’t want to miss this!
Join us tomorrow for $BFRG’s @Xtalks webinar, “Turning AI Recommendations into Clear, Defensible Decisions”
Register here: https://t.co/sWM1Bv5Jur
$BFRG today unveiled bfARENAS™️ , a new scenario-based decision engine for pharmaceutical portfolio strategy and clinical trial design, bolstering its end-to-end AI intelligence workflow.
Read the full release here: https://t.co/L22UVeFq3K